Cotrimoxazole induced adverse cutaneous reaction during the treatment of AIDS associated pneumocystosis;Toxidermies au cotrimoxazole et traitement curatif de la pneumocystose du SIDA

Revue des Maladies Respiratoires

Volumn 13, Issue 2, 1996, Pages 101-106

  Caumes, E ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Adverse cutaneous reactions; AIDS; Pneumocystosis; Trimethoprimesulfamethoxazole

Indexed keywords

ANTIINFECTIVE AGENT; COTRIMOXAZOLE; CORTICOSTEROID;

AIDS RELATED COMPLEX; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; HUMAN; INCIDENCE; PATHOPHYSIOLOGY; PNEUMOCYSTIS PNEUMONIA; REVIEW; RISK FACTOR; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; ACETYLATOR PHENOTYPE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CORTICOSTEROID THERAPY; DRUG HYPERSENSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PNEUMOCYSTOSIS; RASH; SKIN MANIFESTATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; DRUG ERUPTIONS; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; INCIDENCE; PNEUMONIA, PNEUMOCYSTIS; RISK FACTORS; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0029666193     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. COOPMAN S, JOHNSON RA, PLATT R, STERN RS : Cutaneous disease and drug reactions in HIV infections. N Engl J Med 1993;328:1670-4.
2. CARR A, SWANSON C, PENNY R, COOPER DA : Clinical and laboratory markers of hypersensibility to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis 1993;167:180-5.
3. MITSUYASU R, GROOPMANN J : Cutaneous reaction to trimethoprim-sulfamethoxazole in patients with AIDS and Kaposi's sarcoma. N Engl J Med 1983;308:1535-6.
4. GORDIN FM, SIMON GL, WOFSY CB, MILLS J : Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:495-9.
5. KOVACS JA, HIEMENZ JW, MACHER AM et al. : Pneumocystis carinii pneumonia : a comparison between patients with acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984;100:663-71.
6. SMALL CB, HARRIS CA, FRIEDLAND GH, KLEIN RS : The treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Arch Intern Med 1985;145:837-40.
7. SATTLER FR, COWAN R, NIELSEN DM, RUSKIN J : Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome : a prospective non cross-over study. Ann Intern Med 1988;109:280-7.
8. LEE BL, MEDINA I, BENOWITZ NL, JACOB III P, WOFSY CB, MILLS J : Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome. Evidence of drug interactions. Ann Intern Med 1989;110:606-11.
9. MEDINA I, MILLS J, LEOUNG G et al. : Oral therapy for Pneumocystis carinii pneumonia in acquired immunodeficiency syndrome. N Engl J Med 1990;323:779-82.
10. HUGHES W, LEOUNG G, KRAMER F et al. : Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993;328:1521-7.
11. TOMA E, FOURNIER S, DUMONT M, BOLDUC P, DESCHAMPS H : Clindamycin/primaquine versus trimethoprim-sulfamethoxazole as primary therapy for Pneumocystis carinii pneumonia in AIDS : a randomized, double blind, pilot trial. Clin Infect Dis 1993;17:178-84.
12. ROUDIER C, CAUMES E, ROGEAUX O, BRICAIRE F, GENTILINI M : Adverse cutaneous reactions to trimethoprimsulfamethoxazole in patients with the acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia. Arch Dermatol 1994;130:1383-6.
13. HUGHES WT, FELDMAN S, CHAUDHARY SC, OSSI MG, COX F, SANYAL SK : Comparison of pentamidine isethionate with trimethoprim-sulfamethoxazole in treatment of Pneumocystis carinii pneumonia. J Pediatr 1978;92:285-91.
14. WINSTON DJ, LAU WK, GALE RP, YOUNG LS : Trimethoprim-sulfamethoxazole for treatment of Pneumocystis carinii pneumonia. Ann Intern Med 1980;92:762-9.
15. JICK H : Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis 1982;4:426-8.
16. ROUJEAU JC, STERN RS : Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85.
17. PUTTERMAN C, RAHAV G. SHALIT M, RUBINOW A : « Treating through » hypersensitivity to cotrimoxazole in AIDS patients. Lancet 1990;ii:52.
18. SAÏAG P, CAUMES E, CHOSIDOW O, REVUZ J, ROUJEAU JC : Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992;26:567-74.
19. CAUMES E, GENTILINI M : Fatal toxic epidermal necrolysis in AIDS patients. Clin Infect Dis 1995;21:240.
20. DE HOVITZ J, JOHNSON W, PAPE J : Cutaneous reactions to trimethoprim-sulfamethoxazole in Haïtians. Ann Intern Med 1985;103:479-80.
21. COLEBUNDERS R, ISALEY L, BILA K et al. : Cutaneous reactions to trimethoprim-sulfamethoxazole in African patients with the acquired immunodeficiency syndrome. Ann Intern Med 1987;107:599-600.
22. CAUMES E, BOCQUET H, GENTILINI M : Toxidermies et infection par le VIH. Med Mal Infect 1995;25:488-99.
23. DANNEMANN B, MCCUTCHAN JA, ISRAELSKI D et al. : Treatment of toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992;116:33-43.
24. HARDY WD, FEINBERG J, FINKELSTEIN DM et al. : A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;327.1842-8.
25. CARR A, PENNY R, COOPER DA : Efficacy and safety of rechallenge with low-dose trimethoprim-sulfamethoxazole in previously hypersensitive HIV-infected patients. AIDS 1993;7:65-71.
26. CARR A, TINDALL B, PENNY R, COOPER DA : Patterns of multiple-drug hypersensitivities in HIV-infected patients. AIDS 1993;7:1532-3.
27. CAUMES E, BOCQUET H, GUERMONPREZ G, ROGEAUX O, BRICAIRE F, KATLAMA C, GENTILINI M : Adverse cutaneous reactions to pyrimethamine-sulfadiazine and pyrimethamineclindamycine in AIDS patients with toxoplasmic encephalitis. Clin Infect Dis 1995;21:656-8.
28. KELLY JW, DOOLEY DP, LATTUADA CP, SMITH CE : A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus. Clin Infect Dis 1992;14:1034-9
29. BATTEGAY M, OPRAVIL M, WÜTHRICH B, LUTHY R : Rash with amoxycillin-clavulanate therapy in HIV-infected patients. Lancet 1989;ii:1100.
30. KENNEDY CA, PIMENTEL JA, LEWIS DE, ANDERSON MD, WEISS PJ, OLDFIELD III EC : Crossover of human immunodeficiency virus-infected patients from aerosolized pentamidine to trimethoprim-sulfamethoxazole : lack of hematologic toxicity and relation ship of side-effects to CD4+ lymphocyte count. J Infect Dis 1993;168:314-7.
31. AGUILAR X, RUIZ J, CLOTET B, ROIG J : The use of corticosteroids in the control of the adverse effects of cotrimoxazole in AIDS patients suffering from PCP. AIDS 1991;5:777-8.
32. CAUMES E, ROUDIER C, ROGEAUX O, BRICAIRE F, GENTILINI M : Effect of corticosteroids on the incidence of adverse cutaneous reactions to trimethoprim-sulfamethoxazole during treatment of AIDS associated Pneumocystis carinii pneumonia. Clin Infect Dis 1994;18:319-23.
33. WALMSLEY S, LEVINTON C, BRUNTON J et al. : A multicenter randomized double-blind placebo-controlled trial of adjunctive corticosteroids in the treatment of Pneumoscystis carinii pneumonia complicating the acquired immune deficiency syndrom. J Acquired Immune Defic Syndrom 1995;8:348-57.
34. TOMA E, FOURNIER S : Adverse reactions to co-trimoxazole in HIV infection. Lancet 1991;338:954.
35. LEE BL, SAFRIN S : Interactions and toxicities of drugs used in patients with AIDS. Clin Infect Dis 1992;14:773-9.
36. CARR A, GROSS AS, HOSKINS JM, PENNY R, COOPER DA : Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS 1994;8:333-7.
37. RIEDER MJ, SHEAR NH, KANEE A, TANG BK, SPIELBERG SP : Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991;49:13-7.
38. CLARK DWJ : Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs 1985;29:342-75.
39. RIEDER MJ, UETRECHT J, SHEAR NH, CANNON M, MILLER M, SPIELBERG SP : Diagnosis of sulfonamide hypersensitivity reactions by in vitro « rechallenge » with hydroxylamine metabolites. Ann intern Med 1989;110:286-9.
40. CARR A, TINDALL B, PENNY R, COOPER DA : In vitro cytotoxicity as a marker of hypersensitivity to sulfamethoxazole in patients with HIV. Clin Exp Immunol 1993;94:21-5.
41. SHEAR NH, SPIELBERG SP: In vitro evaluation of a toxic metabolite of sulfadiazine. Can J Physiol Pharmacol 1985;63:1370-2.
42. BUHL R, JAFFE HA, HOLROYD KJ et al. : Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 1989;ii:1294-8.
43. VAN DER VEN AJAM, KOOPMANS PP, VREE TB, VAN DER MEER JWM : Adverse reactions to cotrimoxazole in HIV infection. Lancet 1991;338:431-3.
44. RIEDER MJ, KRAUSE R, BIRD IA, DEKABAN GA : Toxicity of sulfonamide-reactive metabolites in HIV-infected, HTLV-infected, and non infected cells. J Acquired immunodeficiency syndromes and Human retrovirology 1995;8:134-40.
45. ABSAR N, DANESHVAR H, BEALL G : Desensitization to trimethoprim-sulfamethoxazole in HIV-infected patients. J Allergy Clin Immunol 1994;93:1001-5.